Equillium, Inc. · NASDAQ:EQ
Equillium — Technical Presentation (November 2022)
23 slides from Equillium's technical presentation, Nov 3, 2022
Slide 1: EQ101: A Multi-specific Cytokine Inhibitor to Treat Alopecia Areata
EQ101: A Multi-specific Cytokine Inhibitor to Treat Alopecia Areata
Slide 2: Cytokine Signaling – A Complex and Combinatorial Issue
Cytokine Signaling – A Complex and Combinatorial Issue This same complexity shown in how cytokines signal to regulate immune homeostasis presents unique drug development challenges when treating disease e.g., anti-IL-4Rα Three important characteristics of most cytokines are: Use of shared receptors
Slide 3: Discovery Platform – Multi-cytokine Inhibitors
Discovery Platform – Multi-cytokine Inhibitors Novel product platform addresses the limitations of single-target biologics and broadly immunosuppressive therapies (e.g. JAKi) through peptide-based multi-cytokine inhibition • Targeting validated biological and disease pathways • Leveraging in-house e
Slide 4: Optimized Modality Compared to mAbs and JAK Inhibitors
Optimized Modality Compared to mAbs and JAK Inhibitors Multi-cytokine inhibition at the receptor-level without the broad immuno-suppression and off target safety liabilities of JAK inhibitors mAb JAK inhibitor EQ Peptides Inhibits one cytokine Inhibits 50+ cytokines Inhibits selective cytokines Insu
Slide 5: Targeting the gc Receptor, a Key Cytokine Signaling Hub
Targeting the gc Receptor, a Key Cytokine Signaling Hub Cytokines signaling through the common gamma (gc) chain exhibit redundancy as well as synergy that has been shown to be important to pro-inflammatory disease states Lee et al., Cancers., 2011 5
Slide 6: EQ101: A First-in-class Tri-Specific Cytokine Inhibitor
EQ101: A First-in-class Tri-Specific Cytokine Inhibitor Receptor Therapeutic Active Structural Functional Target Activity Domain Modifications Fusions gC Antagonist Linear Peptide None None GP130 PEGylation Β-Chain Non-natural AA’s IL-10R2 Helical Peptide Lipidation IL-12RB1 Stabilizing staple Album
Slide 7: EQ101 Validates EQ’s Unique Structure-Based Discovery Platform
EQ101 Validates EQ’s Unique Structure-Based Discovery Platform Cytokine-receptor binding interface EQ101 Structured-Domain Peptide High alignment with IL-2 and IL-15 and low alignment cytokine gc receptor with IL-4 correlates with EQ-101’s ability to block IL-2 and IL-15 activity, but not IL-4 activ
Slide 8: EQ101: A First-in-class Tri-Specific Cytokine Inhibitor
EQ101: A First-in-class Tri-Specific Cytokine Inhibitor Inhibition of IL-2, IL-9, and IL-15 biology by EQ101 translates from preclinical models into humans • IL-2 and IL-15 are important to CD8 and NK cell biology, while IL-9 EQ101 PEGylated peptide contributes to inflammation • PEGylated peptide ba
Slide 9: EQ101 Selectively Inhibits gc Cytokines IL-2/IL-9/IL-15
EQ101 Selectively Inhibits gc Cytokines IL-2/IL-9/IL-15 PT-18β NK92 PT-18β and NK92 cells were brought to a resting state by washing and culturing in complete RPMI media in the absence of the cytokine for 6 hrs. Cells were then plated at 1x105 per well in a 96 well plate. Each assay was tested in tr
Slide 10: First-in-Human Studies of EQ101
First-in-Human Studies of EQ101 Phase/Study Study ID Study Title Dosing Regimens Studied Type BNZ-CT-101 Phase 1a First in Human Study in Healthy Volunteers to Single IV doses of: Investigate the Safety, Tolerability, and • 0.2 mg/kg (N=3) First in Human Pharmacokinetics of Single Ascending Doses •
Slide 11: EQ101 Inhibits T cell Leukemia Growth in a Xenograft Model
EQ101 Inhibits T cell Leukemia Growth in a Xenograft Model • IL-2, IL-9, and IL-15 are overexpressed in adult T cell leukemia (ATL) and cutaneous T cell lymphoma (CTCL) where they drive cancer cell proliferation and increased inflammation in the skin1,2,3,4,5 • Blocking IL-2 or IL-15 alone was ineff
Slide 12: Phase 1/2 Proof-of-Concept Study of EQ101 in CTCL Patients
Phase 1/2 Proof-of-Concept Study of EQ101 in CTCL Patients Clinically validated with favorable safety profile, Phase 2/3 ready to address multiple indications with significant unmet medical need Phase 1/2 MAD study in CTCL • Heavily pre-treated population (median of 5 prior systemic treatments) • Do
Slide 13: EQ101 is Clinically Validated in Severe Dermatological Disease
EQ101 is Clinically Validated in Severe Dermatological Disease EQ101 reduces IL-2 & IL-15 dependent cells and inflammation with improvements in skin lesions and overall response rate (ORR) comparing favorably with benchmark drugs MAVORIC trial evaluating mogamulizumab and vorinostat provides the mos
Slide 14: Alopecia Areata - Pathophysiology
Alopecia Areata - Pathophysiology The targets for EQ101 inhibition (IL-2, IL-9 and IL-15) are key drivers of disease leading to a cycle of increased IFN-g production and loss of hair in alopecia areata patients Activated T cells secrete IFN-g IFN-g binds to receptor on hair follicle Hair follicle ep
Slide 15: gc Cytokines Key to Pathogenesis of Alopecia Areata
gc Cytokines Key to Pathogenesis of Alopecia Areata C3H/HeJ mice with long standing AA were treated topically with INCB039110 (JAK1i), CEP-33779 (JAK2i), or PF-06651600 (JAK3i) or control daily for 12 weeks, in cohorts of 4 mice per group. (A) Representative images of individual JAK inhibitor– or ve
Slide 16: EQ101 Inhibits Immune-Mediated Hair Loss in a Mouse Model
EQ101 Inhibits Immune-Mediated Hair Loss in a Mouse Model EQ101 is more effective than ruxolitinib at hair regrowth and suppression of cytotoxic CD8+ T- cells in humanized alopecia model EQ101 Improves Hair Regrowth EQ101 Reduces CD8+ Cytotoxic T-cell Activation Marker NKG2D 2 mg/kg IV 2x/week x 2 w
Slide 17: EQ101 Provides Complete Cytokine-mediated Signal Inhibition
EQ101 Provides Complete Cytokine-mediated Signal Inhibition JAKi effect on cytokine signaling is broad yet incomplete, whereas EQ101 can inhibit multiple downstream pathways for a more potent suppression of cytokine signaling EQ101 IL-2 IL-2 JAKi - IL-2 +EQ101 - IL-2 +ruxolitinib P ERK PIK3/AKT In-h
Slide 18: EQ101 To Treat Alopecia Areata
EQ101 To Treat Alopecia Areata EQ101 is a differentiated approach to treating alopecia areata with an attractive target product profile and positioned as an alternative or substitute to JAK inhibitors JAK Inhibitor Other • Approach in alopecia areata most JAK Inhibitors Alternative Mechanisms analog
Slide 19: Phase 2 Study of EQ101 in Adults With Moderate to Severe AA
Phase 2 Study of EQ101 in Adults With Moderate to Severe AA Phase 2 open label study to evaluate safety and efficacy after 24 weeks of treatment Primary Objective • Evaluate the safety and tolerability of EQ101 in adult subjects with moderate to severe alopecia areata over 24 Screening Treatment Per
Slide 20: Phase 2 Study Sites
Phase 2 Study Sites Northern Territory Queensland Western Australia Veracity Clinical Research Dr. Lynda Spelman South Australia Fremantle Dermatology Dr. Kurt Gebauer New South Wales Premier Dermatology Dr. Dede Murrell Victoria Sinclair Dermatology Dr. Rodney Sinclair Lead Investigator 20
Slide 21: EQ101 - Summary
EQ101 - Summary MCi Platform • EQ101 is a potent and selective first-in-class tri-specific inhibitor of IL-2, IL-9 and IL-15 Clinically validated • Safe, well-tolerated and effective in treating severe dermatological inflammation in CTCL patients Strong biologic rationale in alopecia Areata • The cy
Slide 22: Acknowledgments & Q&A
Acknowledgments & Q&A • NIH Research Teams • Dr. Nazli Azimi (co-founder) • Professor Yutaka Tagaya (co-founder) • Bioniz Research Team • Equillium Research Team • KOLs and advisors for alopecia areata trial • Phase 2 Trial sites and PIs • Patients of the clinical trials • Our investors 22
Slide 23: Thank you
Thank you www.equilliumbio.com